Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Predictors of Significant Liver Fibrosis in People with Chronic Hepatitis C Who Inject Drugs in the Czech Republic

S. Frankova, N. Uzlova, D. Merta, V. Pitova, J. Sperl

. 2023 ; 13 (4) : . [pub] 20230402

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010060

Grantová podpora
The project for development of research organization 00023001 Ministry of Health, Czech Republic

BACKGROUND AND OBJECTIVES: HCV infection often remains untreated in people who inject drugs (PWID), albeit they may present with advanced liver fibrosis at a young age. We aimed to assess the rate of patients with significant fibrosis in PWID starting anti-HCV therapy and identify the factors associated with severe fibrosis. METHODS: The cohort of 200 patients was divided into two groups: F0-F2 (N = 154, 77%), patients with liver stiffness measurement (LSM) < 10.0 kPa, and F3-F4 (N = 46, 23%), with LSM ≥ 10.0 kPa, indicating significant liver fibrosis. RESULTS: In group F3-F4, there were significantly more males, and the patients were older, with a higher BMI. The number of long-term abstaining patients was significantly higher in group F3-F4 compared with group F0-F2, as well as the proportion of patients reporting harmful drinking. Obesity (OR 4.77), long-term abstinence from illicit drugs (OR 4.06), harmful drinking (OR 2.83), and older age (OR 1.17) were significant predictors of advanced fibrosis in PWID starting anti-HCV therapy. CONCLUSIONS: A quarter of PWID presented with significant liver fibrosis at treatment initiation. Obesity, long-term drug abstinence, harmful drinking, and older age contributed to significant liver fibrosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010060
003      
CZ-PrNML
005      
20250402152946.0
007      
ta
008      
230707s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/life13040932 $2 doi
035    __
$a (PubMed)37109461
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fraňková, Soňa $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $1 https://orcid.org/0000000214625920 $7 xx0329475
245    10
$a Predictors of Significant Liver Fibrosis in People with Chronic Hepatitis C Who Inject Drugs in the Czech Republic / $c S. Frankova, N. Uzlova, D. Merta, V. Pitova, J. Sperl
520    9_
$a BACKGROUND AND OBJECTIVES: HCV infection often remains untreated in people who inject drugs (PWID), albeit they may present with advanced liver fibrosis at a young age. We aimed to assess the rate of patients with significant fibrosis in PWID starting anti-HCV therapy and identify the factors associated with severe fibrosis. METHODS: The cohort of 200 patients was divided into two groups: F0-F2 (N = 154, 77%), patients with liver stiffness measurement (LSM) < 10.0 kPa, and F3-F4 (N = 46, 23%), with LSM ≥ 10.0 kPa, indicating significant liver fibrosis. RESULTS: In group F3-F4, there were significantly more males, and the patients were older, with a higher BMI. The number of long-term abstaining patients was significantly higher in group F3-F4 compared with group F0-F2, as well as the proportion of patients reporting harmful drinking. Obesity (OR 4.77), long-term abstinence from illicit drugs (OR 4.06), harmful drinking (OR 2.83), and older age (OR 1.17) were significant predictors of advanced fibrosis in PWID starting anti-HCV therapy. CONCLUSIONS: A quarter of PWID presented with significant liver fibrosis at treatment initiation. Obesity, long-term drug abstinence, harmful drinking, and older age contributed to significant liver fibrosis.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Uzlova, Nikola $u Department of Internal Medicine, University Hospital Kralovske Vinohrady, 10034 Prague, Czech Republic $u Third Faculty of Medicine, Charles University, 10034 Prague, Czech Republic
700    1_
$a Merta, Dusan $u Cardiothoracic Anaesthesiology and Intensive Care, Department of Anaesthesiology and Intensive Care Medicine, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic
700    1_
$a Pitova, Veronika $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic
700    1_
$a Sperl, Jan $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 12108 Prague, Czech Republic $1 https://orcid.org/0000000186192610 $7 xx0071614
773    0_
$w MED00186366 $t Life $x 2075-1729 $g Roč. 13, č. 4 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37109461 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20250402152942 $b ABA008
999    __
$a ok $b bmc $g 1958619 $s 1196324
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 13 $c 4 $e 20230402 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
GRA    __
$a The project for development of research organization 00023001 $p Ministry of Health, Czech Republic
LZP    __
$a Pubmed-20230707

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace